Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year High – Should You Buy?

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as $19.20 and last traded at $19.13, with a volume of 246957 shares trading hands. The stock had previously closed at $18.77.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TEVA shares. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Wednesday, July 10th. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Barclays raised their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Price Performance

The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The company has a fifty day simple moving average of $18.03 and a two-hundred day simple moving average of $17.06.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the business. New Covenant Trust Company N.A. acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $30,000. UMB Bank n.a. grew its position in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $52,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.